This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bulugahapitiya, U. Articles by Idris, I. Search for Related Content PubMed PubMed Citation Articles by Bulugahapitiya, U. Articles by Idris, I. Pubmed/NCBI databases Medline Plus Health Information Diabetes Complications Metabolic Syndrome Social Bookmarking                         What's this?

The clinical impact of identifying metabolic syndrome in patients with diabetes: a cross-sectional study

Sherwood Forest Hospitals Foundation Trust, Nottinghamshire, NG17 4JL, UK.

Sajith Siyambalapitiya

Sherwood Forest Hospitals Foundation Trust, Nottinghamshire, NG17 4JL, UK.

Jabulani Sithole

Trent RDSU, University of Nottingham, Nottingham, NG7 2UH, UK.

Devaka J Fernando

Sheffield Hallam University, Sheffield, S1 1WB, UK.

Iskandar Idris

Sherwood Forest Hospitals Foundation Trust, Nottinghamshire, NG17 4JL, UK.

The objectives of the study were to determine whether identifying patients with metabolic syndrome (MetS) (as defined by International Diabetes Federation [IDF] criteria) among patients with diabetes would affect the decision to prescribe statin for primary prevention of cardiovascular disease (CVD), based on currently available public health guidelines.

We analysed the most recent recorded CVD risk profiles obtained from electronic patient files from 304 general practices in England and Wales. Of 60,258 patients with diabetes, 11,005 men and women aged 30–74 years fulfilled criteria for primary CVD prevention and were not on lipid-lowering drugs. Outcome data were extrapolated to an estimated national diabetes prevalence of 3.6%.

Identifying MetS in this group of patients would produce an additional 29,536 (8.4%; 95% CI: 7.7, 9.0), 104,288 (29.6%; 95% CI: 28.5, 30.7) and 147, 328 (41.9%; 95% CI: 40.8, 43.0) patients nationally who would not have been eligible otherwise for primary CVD prevention strategies with statins, based on the Joint British Societies’, the National Institute for Health and Clinical Excellence and the General Medical Services contract guidelines, respectively. The sensitivity and positive predictive value of these different strategies to detect metabolic syndrome were 87.5% and 69.1%; 57.3% and 76.8%; and 37.8% and 70.2%, respectively.

In conclusion, among individuals with diabetes, identifying patients with MetS may further increase the use of statin therapy for primary CVD prevention.

Key Words: cardiovascular disease • diabetes • metabolic syndrome • primary prevention • statin.

Diabetes and Vascular Disease Research, Vol. 6, No. 1, 21-24 (2009)
DOI: 10.3132/dvdr.2009.004


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?